BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Lonardo A. Precision medicine in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2022;37:1175-8. [PMID: 35801994 DOI: 10.1111/jgh.15850] [Reference Citation Analysis]
2 Nakanishi N, Hashimoto Y, Okamura T, Ohbora A, Kojima T, Hamaguchi M, Fukui M. A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep 2021;11:19992. [PMID: 34620897 DOI: 10.1038/s41598-021-99036-y] [Reference Citation Analysis]
3 Karamfilova V, Assyov Y, Nedeva I, Gateva A, Ivanova I, Cherkezov N, Mateva L, Kamenov Z. Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2021. [PMID: 34818080 DOI: 10.1089/met.2021.0086] [Reference Citation Analysis]
4 Geethangili M, Lin CW, Mersmann HJ, Ding ST. Methyl Brevifolincarboxylate Attenuates Free Fatty Acid-Induced Lipid Metabolism and Inflammation in Hepatocytes through AMPK/NF-κB Signaling Pathway. Int J Mol Sci 2021;22:10062. [PMID: 34576229 DOI: 10.3390/ijms221810062] [Reference Citation Analysis]
5 Liu Y, Wang W. Sex-specific contribution of lipid accumulation product and cardiometabolic index in the identification of nonalcoholic fatty liver disease among Chinese adults. Lipids Health Dis 2022;21:8. [PMID: 35027066 DOI: 10.1186/s12944-021-01617-3] [Reference Citation Analysis]
6 Robeva R, Mladenović D, Vesković M, Hrnčić D, Bjekić-Macut J, Stanojlović O, Livadas S, Yildiz BO, Macut D. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas 2021;151:22-30. [PMID: 34446275 DOI: 10.1016/j.maturitas.2021.06.012] [Reference Citation Analysis]
7 Pérez-mayorga M, Lopez-lopez JP, Chacon-manosalva MA, Castillo MG, Otero J, Martinez-bello D, Gomez-arbelaez D, Cohen DD, Lopez-jaramillo P, Ravaioli F. Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-7. [DOI: 10.1155/2022/1782221] [Reference Citation Analysis]
8 Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH. Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. J Clin Endocrinol Metab 2022:dgac321. [PMID: 35587339 DOI: 10.1210/clinem/dgac321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ushio K, Mikami Y, Obayashi H, Fujishita H, Fukuhara K, Sakamitsu T, Hirata K, Ikuta Y, Kimura H, Adachi N. Decreased Muscle-to-Fat Mass Ratio Is Associated with Low Muscular Fitness and High Alanine Aminotransferase in Children and Adolescent Boys in Organized Sports Clubs. J Clin Med 2021;10:2272. [PMID: 34073883 DOI: 10.3390/jcm10112272] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zhang S, Xu M, Zhang W, Liu C, Chen S. Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications. Int J Mol Sci 2021;22:6110. [PMID: 34204038 DOI: 10.3390/ijms22116110] [Reference Citation Analysis]
11 Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci 2021;22:6627. [PMID: 34205674 DOI: 10.3390/ijms22126627] [Reference Citation Analysis]
12 Du T, Fang Q, Zhang Z, Zhu C, Xu R, Chen G, Wang Y. Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway. Metabolites 2022;12:55. [PMID: 35050176 DOI: 10.3390/metabo12010055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
14 Huang YH, Wang FS, Wang PW, Lin HY, Luo SD, Yang YL. Heat Shock Protein 60 Restricts Release of Mitochondrial dsRNA to Suppress Hepatic Inflammation and Ameliorate Non-Alcoholic Fatty Liver Disease in Mice. Int J Mol Sci 2022;23:577. [PMID: 35009003 DOI: 10.3390/ijms23010577] [Reference Citation Analysis]
15 De Chiara F, Ferret-Miñana A, Ramón-Azcón J. The Synergy between Organ-on-a-Chip and Artificial Intelligence for the Study of NAFLD: From Basic Science to Clinical Research. Biomedicines 2021;9:248. [PMID: 33801289 DOI: 10.3390/biomedicines9030248] [Reference Citation Analysis]
16 Ahmed H, Umar MI, Imran S, Javaid F, Syed SK, Riaz R, Hassan W. TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop. Exp Mol Pathol 2021;124:104733. [PMID: 34914973 DOI: 10.1016/j.yexmp.2021.104733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Vachher M, Bansal S, Kumar B, Yadav S, Arora T, Wali NM, Burman A. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. J Cell Biochem 2022. [PMID: 35818831 DOI: 10.1002/jcb.30252] [Reference Citation Analysis]
18 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kositamongkol C, Charernboon T, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Charatcharoenwitthaya P, Phisalprapa P. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome. Medicine (Baltimore) 2021;100:e27640. [PMID: 34871234 DOI: 10.1097/MD.0000000000027640] [Reference Citation Analysis]
20 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Targher G. What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites. 2020;10. [PMID: 33049948 DOI: 10.3390/metabo10100397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Spearman CW, Abdo A, Ambali A, Awuku YA, Kassianides C, Lesi OA, Ndomondo-Sigonda M, Onyekwere CA, Rwegasha J, Shewaye AB, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1047-56. [PMID: 34508669 DOI: 10.1016/S2468-1253(21)00296-X] [Reference Citation Analysis]
23 Zhong L, Wu C, Li Y, Zeng Q, Lai L, Chen S, Tang S. Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses. Therapeutic Advances in Chronic Disease 2022;13:204062232210835. [DOI: 10.1177/20406223221083508] [Reference Citation Analysis]
24 Lonardo A. Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease. Clinical and Translational Dis 2021;1. [DOI: 10.1002/ctd2.9] [Reference Citation Analysis]
25 Ma Q, Yang F, Ma B, Jing W, Liu J, Guo M, Li J, Wang Z, Liu M. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. Hepatol Int 2021;15:127-36. [PMID: 33512644 DOI: 10.1007/s12072-020-10132-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Igreja Sá IC, Tripska K, Hroch M, Hyspler R, Ticha A, Lastuvkova H, Schreiberova J, Dolezelova E, Eissazadeh S, Vitverova B, Najmanova I, Vasinova M, Pericacho M, Micuda S, Nachtigal P. Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver. Int J Mol Sci 2020;21:E9021. [PMID: 33261044 DOI: 10.3390/ijms21239021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Pellicori P, Vaduganathan M, Ferreira JP, Zannad F, Sanyal AJ. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Diabetes Metab 2021;:101281. [PMID: 34543735 DOI: 10.1016/j.diabet.2021.101281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Colca JR, Scherer PE. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. Mol Metab 2021;55:101409. [PMID: 34863942 DOI: 10.1016/j.molmet.2021.101409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Jeong SM, Lee HR, Jang W, Kim D, Yoo JE, Jeon KH, Jin SM, Han K, Shin DW. Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease. Parkinsonism Relat Disord 2021;93:19-26. [PMID: 34763304 DOI: 10.1016/j.parkreldis.2021.10.030] [Reference Citation Analysis]
31 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
32 Uchida T, Fujiwara K, Nishioji K, Kobayashi M, Kano M, Seko Y, Yamaguchi K, Itoh Y, Kadotani H. Medical checkup data analysis method based on LiNGAM and its application to nonalcoholic fatty liver disease. Artificial Intelligence in Medicine 2022. [DOI: 10.1016/j.artmed.2022.102310] [Reference Citation Analysis]
33 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
34 Whitcher B, Thanaj M, Cule M, Liu Y, Basty N, Sorokin EP, Bell JD, Thomas EL. Precision MRI phenotyping enables detection of small changes in body composition for longitudinal cohorts. Sci Rep 2022;12:3748. [PMID: 35260612 DOI: 10.1038/s41598-022-07556-y] [Reference Citation Analysis]
35 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
36 Morán-Costoya A, Proenza AM, Gianotti M, Lladó I, Valle A. Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk. Antioxid Redox Signal 2021;35:753-74. [PMID: 33736456 DOI: 10.1089/ars.2021.0044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
37 Monelli F, Besutti G, Djuric O, Bonvicini L, Farì R, Bonfatti S, Ligabue G, Bassi MC, Damato A, Bonelli C, Pinto C, Pattacini P, Giorgi Rossi P. The Effect of Diffuse Liver Diseases on the Occurrence of Liver Metastases in Cancer Patients: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:2246. [PMID: 34067076 DOI: 10.3390/cancers13092246] [Reference Citation Analysis]
38 Alqahtani SA, Broering DC, Alghamdi SA, Bzeizi KI, Alhusseini N, Alabbad SI, Albenmousa A, Alfaris N, Abaalkhail F, Al-Hamoudi WK. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:245. [PMID: 34074270 DOI: 10.1186/s12876-021-01828-z] [Reference Citation Analysis]
39 de Groot JM, Geurtsen ML, Santos S, Jaddoe VWV. Ethnic disparities in liver fat accumulation in school-aged children. Obesity (Silver Spring) 2022;30:1472-82. [PMID: 35785476 DOI: 10.1002/oby.23478] [Reference Citation Analysis]
40 Frisardi V, Matrone C, Street ME. Metabolic Syndrome and Autophagy: Focus on HMGB1 Protein. Front Cell Dev Biol 2021;9:654913. [PMID: 33912566 DOI: 10.3389/fcell.2021.654913] [Reference Citation Analysis]